CCM
IPXL

Catapult Capital Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Catapult Capital Management’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-40,000
Closed -$1.06M – 275
2014
Q1 		$1.06M Buy
+40,000
New +$1,000K 0.21% 108

Other funds holding IPXL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Catapult Capital Management's IPXL Position: Q2 2014 in Review

Catapult Capital Management sold out of Impax Laboratories, Inc. (IPXL) in Q2 2014, closing a stake of 40,000 shares — an estimated $1.06M sold.

Catapult Capital Management first reported a position in IPXL in Q1 2014 and held it in 1 quarter. The position peaked at $1.06M in Q1 2014. 185 funds tracked by Wall St. Rank hold IPXL as of Q2 2014.

  • Catapult Capital Management reported no remaining Impax Laboratories, Inc. position as of Q2 2014 after selling out during the quarter.
  • Catapult Capital Management sold 40,000 Impax Laboratories, Inc. shares in Q2 2014, an estimated $1.06M.
  • Catapult Capital Management first reported a position in Impax Laboratories, Inc. in Q1 2014 and held it in 1 quarter.
  • Catapult Capital Management's Impax Laboratories, Inc. position peaked at $1.06M in Q1 2014.
  • 185 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2014.

Based on Catapult Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.